

(2007/12/31 2007/6/11)

(SDS) (Sephadex G-75)

(%50-25)

(49185) (48123)

HDL (47305)

.(49907)

HDL

(10) (12)

(25 C°) (30 C°) (7.6) (7.2)

(238.1 U/ml) (243.9 U/ml) $V_{\max}$ (4.5 mM) (4mM)

. (3.26 mM) (3.07 mM) K_m

Isolation and Purification of Arylesterase From Normal Blood Serum(Part II)

Rana F. Jasim

*Department of Chemistry
College of Education of Girl
Mosul University*

Thikra A. Allwsh

*Department of Chemistry
College of Science
Mosul University*

ABSTRACT

The research included isolation and purification of arylesterase from normal blood serum. The molecular weight of the partially purified enzyme was determined by gel filtration using (Sephadex G-75) and SDS electrophoresis techniques. It was found that the first proteinous peak separated from ammonium sulfate saturation of serum with (25 –50%) using gel filtration and SDS electrophoresis techniques had apparent molecular weight of (48123 d) and (49185d) respectively. The second proteinous peak separated from serum by gel filtration technique had apparent molecular weight (47305 d). On the other hand, the first proteinous peak separated from HDL serum had a molecular weight (49907 d).

The optimum conditions of arylesterase for the two peaks separated from HDL and ammonium sulfate precipitation solution showed an optimum reaction incubation time at (12),(10) minutes, an optimum pH at (7.2),(7.6), an optimum temperature (30 C°), (25 C°) and optimum substrate concentration (4 mM), (4.5 mM) and V_{max} value (243.9U/ml), (238.1 U/ml) and K_m value (3.07 mM), (3.26 mM) respectively.

High density lipoprotein (HDL)

HDL

(-N)

HDL

.(Kudchodkar et al., 2000; Valabhji et al., 2001)

(Gan et al., 1991 ; Brushia et al., 2001 ; Gouedard et al., 2003)

Ozols

(354)

Glycoprotein

.

(350)

(1999)

(2004) Davies Aviram

HDL

(Cysteine)

(-SH) Sulfhydryl

.....

(284)

LDL

(Aviram et al., 2000; Tomas et al., 2000)

Ca⁺²

.(Billecke et al., 2000)

Ca⁺²

Isoenzyme

(R , Q)

) (192)

(A)

(

((M , L)) (55)

(B)

.(La Du et al., 1993 ; Sen – Banerjee et al., 2000)

.

:

23

(300 ml)

.

:

HDL (Crepaldi et al., 1978)

LDL IDL VLDL

HDL

(Mg⁺⁺)

.

:

(1961) Weeb Dioxin

(%75-0)

.

:

(9.5 ml) (1978) Plummer
(%50–25)
(0.1 M) (2.5 L)

.

:

.(Andrews, 1965)

: . 1

(Sephadex G–75) (100 x 2cm)
. (95cm)

: . 2

. (7 ml) (Serum) . A
(8 ml)() HDL . B
. C
. (9.6 ml) () (%50–25)

: . 3

(2ml)
(4min) (52.5ml/h)
(280nm)

.

:

(Lyophilizer)

. (–20C°)

:

:

.....

(Tris-HCl)

(4 C°) (-4 C°)

(30-35 C°)

:SDS

SDS

.(1970) Laemmli

:

Pollack Schacterle

(1951)

(1973)

.

:

(2000)

Tomas

:

Arylesterase

Phenyl acetate + H₂O



Phenol + Acetic acid

(270 nm)

.(Al-Robaiey,2006)

(Phenol)

:(U)

.

:

: . 1

.(Plummer, 1978) (Glycoprotein)

: . 2

.(1973) Richmond

:HDL . 3

.HDL (1976) Kostner

: . 4

.(1937) Chardonnet Chabrol

(%25-0)

(%50-25)

(1)

(%75-50)

.(1998)

Pond

:1

(U/mg)***	* U**	mg	ml	
0.693	373.1	538.23	5.5	%25-0
1.08	1029.6	952.67	9.5	%50-25
0.83	915.7	102.01	13	%75-50

(Phenol)

: (U)

(Phenol)

:

:

HDL

: .(1)

289.7 ml = (C)

154.4 ml = (B)

100.7 ml = (A)

(A)

(B)

(B)

(2)

(B)

(2.2)

:

HDL (2)

276.8 ml = (F)

167.4 ml = (E)

143.3 ml = (D)

(D)

(D , E)

(D)

.(E)

.....

(2) HDL

(3) . (3.1) (D)

(%50-25)

(1998) Pond

.

:

.(261.1 ml) (H) (144.1 ml) (G)

(G, H)

(H) (G)

(G)


(G) (2)

(3.08)

.


:2

	%	U/mg	U	mg	ml		
1.0	100	1.242	785.4	632.1	7		
2.2	75.08	2.74	589.7	214.7	214.7	B	
1.0	100	1.242	1122.0	903	10		
1.0	77.4	1.315	869.3	660.6	8	HDL	
3.1	66.5	3.87	746.3	192.7	188	D	
1.0	100	1.242	2805.1	2257.5	25		
1.0	36.7	1.26	1029.6	816.05	9.5	(%50-25)	
1.1	34.05	1.41	955.2	674.5	9.6		
3	17.22	3.82	483.2	126.3	177	G	



(A, B, C)


:1



(D, E, F)

HDL

:2



:3

(G, H) (%50-25)

:

: .1

(G, D, B)

(2000000-204)

(Void volume, Vo)

(Internal volume, Vi)

.(3)


:3

(ml)	()	
85.5	2000000	Blue dextran
118.5	67000	BSA
151.5	45000	Egg albumin
170.8	36000	pepsin enzyme
270.3	5750	Insulin
390.7	204	Tryptophan

(Elution volume) (4)

:

.148.5ml = (G) 146.8ml = (D) 149.3ml = (B)



:4

(B)

.(48123) (G) (49907) (D) (47305)

:SDS

. 2

(G)

SDS

50

(G)


(

186000 -58000)

:(5)

10

.....



SDS

:5

– (C) BSA (B) (A) :
(G)

(4)

(7.9cm) (G) (G)

.(5)

:4


(cm)	()	
2.3	186000	Glucose oxidase
6	67000	BSA
8.3	58000	α -Amylase -

(6)

.(49185) (G)

(48123)

(Gan et al., 1991 ; Pond et al., 1998 ; (49185)
 (49000–43000) . Kujiraoka et al., 2000)
 (45000–43000) (Elosua et al., 2002 ; Vincent–Viry et al., 2003)



.SDS- PAGE :6

:

(D) HDL
 .(5) (Al-Robaiey, 2006) (G)
 HDL V_{max} -
 (243.9 U/ml)
 (3.26 mM) (3.07 mM) K_m - (238.1 U/ml)
 .(Al-Robaiey,2006)

:

(G) (D) HDL
 .(7) (-4C°) (4C°) (30–35C°)

.....

HDL

(7)

(-4C°)

(30-35C°) (4C°)


.(1986) McElveen

HDL

:5

ml	mM	C°	pH (Tris-HCl) (9 mM)	Min	µg/ ml	
2	4	30	7.2	12	9	(D)
2	4.5	25	7.6	10	9	(G)

/ 10



:7

:

: .1

(1999) Ozols

: .2

.(1999) Ozols

:HDL .3

HDL

HDL

: .4

.(1999) Ozols

REFERENCES

- Akgur, S.A., Ozturk, P., Solak, I., Moral, A.R. and Ege, B., 2003. Human serum paraoxonase (PON1) activity in acute organophosphorous insecticide poisoning. *Forensic. Sci. Int.* Vol. 133, No. (1-2): pp.136-140.
- Al-Robaiey, Rana Fadhel Jasim. 2006. Isolation and Studying Arylesterase in Blood Serum and Its Relation with Atherosclerosis in Mosul. (MSC) University of Mosul, College of science, Department of chemistry.
- Andrews, P., 1965. The gel filtration behavior of proteins related to their molecular weight over a wide rang. *J. Biol. Chem.* Vol. 96: 595p.
- Aviram, M. and Davies, K.A., 2004. Paraoxonase 1, 2 and 3, oxidative stress and macrophage foam cell formation during atherosclerosis development. *Free Radical Biology and Medicine.* Vol. 37, No. 9, pp.1304-1316.
- Aviram, M., Hardak, E., Vaya, J., Mahmood, S., Milo, S., Hoffman, A., Billicke, S., Draganov, D. and Rosenblat, M., 2000. Human serum paraoxonases (PON1) Q and R selectivity decrease lipid peroxides in human coronary and carotid atherosclerosis lesions. *Circulation.* Vol. 101, 2510p.
- Billecke, S., Draganov, D., Counsell, R., Stetson, P., Watson, C., Hsu, C. and La Du, B.N., 2000. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. *Drug Metab. Dispos.* Vol. 28, No. 11, pp.1335-1342.
- Brushia, R.J., Forte, T.M., Oda, M.N., La Du, B.N. and Bielicki, J.K., 2001. Baculovirus-mediated expression and purification of human serum paraoxonase 1A. *J. Lipid. Res.* Vol. 42, pp951-958

- Chabrol and Chardonnet, 1937. Cited by Gelson Toro and Philip G. Ackermann (1975). *Prac. Clin. Chem.* Little, Brown and company, Boston, pp.353-354.
- Chemnitius, J.M., Winkel, H., Meyer, I., Schirmmacher, K., Armstrong, V.W., Kreuzer, H. and Zech, R., 1998. Age related decrease of high density lipoproteins (HDL) in women after menopause. Quantification of HDL with genetically determined HDL arylesterase in women with healthy coronary vessels and in women with angiographically verified coronary heart disease. *Med. Klin. (Munich)*. Vol. 93, No. 3, pp.137-145.
- Crepaldi, G., Lefebvre, P.J. and Alberti, K.G.M.M., 1978. *Diabetes, Obesity and Hyperlipidemias*. Academic press Inc., London Ltd., 265p.
- Dioxin, M. and Weeb, E.C., 1961. *Tools of Biochemistry*. T.G. Copperol: 370 John Wiley and Sons. Inc. (1977). 370p.
- Elosua, R., Tomas, M., Senti, M., Molina, L., Vila, J., Anglada, R., Fito, M., Covas, M.I. and Marrugat, J., 2002. Paraoxonase1–192 polymorphism modulates the effects of regular and acute exercise on paraoxanase 1 activity. *J. Lipid Res.* Vol. 43, pp.713-720.
- Fenster, K.M., Parkin, K.L. and Steele, J.L., 2003. Intracellular esterase from lactobacillus casei LILA: nucleotide sequencing, purification, and characterization. *J. Dairy Sci.* Vol. 86, pp.1118-1129.
- Gan, K.N., Smolen, A., Eckerson, H.W. and La Du, B.N., 1991. Purification of human serum paraoxonase / arylesterase evidence for one esterase catalyzing both activities. *Drug Metab. Dispos.* Vol. 19, No. 1, pp.100-106.
- Gouedard, C., Koum–Besson, N., Barouki, R. and morel, Y., 2003. Opposite regulation of the human paraoxonase–1 gene PON–1 by fenofibrate and statins . *Mol. Pharmacol.* Vol. 63, No. 4, pp.945- 956.
- Kostner, G.M., 1976. Enzymatic determination of cholesterol in high density lipoprotein fraction prepared by polyanion precipitation. *Clin. Chem.* Vol. 22, No. 5, 698p.
- Kudchodkar, B.J., Lacko, A.G., Dory, L. and Fungwe, T.V., 2000. Dietary fat modulates serum paraoxonase 1 activity in rats. *J. Nutr.* Vol. 130, No. 10, pp.2427-2433.
- Kujiraoka, T., Oka, T., Ishihara, M., Egashira, T., Fujioka, T., Saito, E., Saito, S., Miller, N.E. and Hattori, H., 2000. A sandwich serum enzyme–linked immunosorbent assay for human serum paraoxonase concentration. *J. Lipid Res.* Vol. 41, pp.1358-1363.
- La Du, B.N., Adkins, S., Kuo, C.L. and Lipsig, D., 1993. Studies on human serum paraoxonase / arylesterase. *Chem. Biol. Interact.* Vol. 87, No. (1-3), pp.25- 34.
- Laemmli, U.K., 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T₄. *Nature*. Vol. 227, 680p.
- Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J., 1951. Protein measurement with folin-phenol reagent. *J. Biol. Chem.* Vol. 193, p.265-275.
- McElveen, J., Mackness, M.L., Colley, C.M., Peard, T., Warner, S. and Walker, C.H., 1986. Distribution of paraoxonase hyderolytic activity in the serum of patients after myocardial infraction. *Clin. Chem.* Vol. 32, No. 4, pp.671-673.
- Ozols, J., 1999. Isolation and complete covalent structure of liver microsomal paraoxonase. *Biochem. J.* Vol. 338, pp.265-272.
- Paragh, G., Seres, I., Balogh, Z., Varga, Z., Karpati, I., Matyus, J., Ujhelyi, L. and Kakuk, G., 1998. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. *Nephron*. Vol. 80, pp.166-170

- Plummer, T.D., 1978. An Introduction of Practical Biochemistry. 2nd ed., McGraw-Hill Book Co., U.K., : 48p., 53p., 174p., 270p., 274p.
- Pond, A.L., Chambers, H.W., Coyne, C.P. and Chambers, J.E., 1998. Purification of two rat hepatic proteins with A-esterase activity toward chlorpyrifos-oxon and paraoxon. *The J. Pharmacol. and Exp. Therapeutics*. Vol. 286, No. 3, pp.1404-1411.
- Richmond, W., 1973. Preparation and properties of a cholesterol oxidase from nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. *Clin. Chem*. Vol. 19, No. 12, pp.1350-1356.
- Rozenberg, O., Shih, D.M. and Aviram, M., 2003. Human serum paraoxonase 1 decrease macrophage cholesterol biosynthesis. *Arterioscler. Thromb. Vasc. Biol*. Vol. 23, 461p.
- Schacterle, G.R. and Pollack, R.L., 1973. A simplified method for the quantitative assay of small amount of protein in biological material. *Anal. Biochem*. Vol. 51, pp.654-655.
- Sen-Banerjee, S., Siles, X. and Campos, H., 2000. Atherosclerosis and lipoproteins: tobacco smoking modifies association between Gln-Arg 192 polymorphism of human paraoxorase gene and risk of myocardial infarction. *Arterioscler. Thromb. Vasc. Biol*. Vol. 20, 2120p.
- Tomas, M., Senti, M., Gareia-Faria, F., Vila, J., Torrents, A., Govas, M. and Marrugat, J., 2000. Effect of simvastatin therapy on paraoxonase activity and related lipoprotein in familial hypercholesterolemic patients. *Arterioscler. Thromb. Vasc. Biol*. Vol. 20, 2113p..
- Valabhji, J., Mccoll, A.J., Schachter, M., Dhanjil, S., Richmond, W. and Elkeles, R.S., 2001. High-density lipoprotein composition and paraoxonase activity in type I diabetes. *Clinical Science*. Vol. 101, pp.659-670.
- Vincent-Viry, M., Sass, C., Bastien, S., Aguilon, D., Siest, G. and Visvikis, S., 2003. PON1-192 phenotype and genotype assessments in 918 subjects of the stanislas cohort studyp. *Clin. Chem. Lab. Med*. Vol. 41, No. 4, pp.535-540.